Expect a negative near-term reaction in AZN and partner Ionis (not directly named in filing) as the ATTR-CM program is now at risk. The monotherapy subgroup signal provides a potential path forward, but the lack of benefit on top of stabiliser is a significant headwind. Monitor the ESC Congress in August for further data and regulatory strategy updates.
Drug in focus
AZN drug pipeline →Wainua
▼ Bearish Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved (Dec 2023 in US; March 2025 in EU). ATTR-CM indication now likely delayed 3-5+ years if pursued at all.
- Next catalyst
- None dated
What to watchWainua's CARDIO-TTRansform Phase 3 failure in ATTR-CM (July 9, 2026) effectively closes off the much larger cardiomyopathy opportunity. Focus on the August 2026 ESC presentation for whether the monotherapy subgroup signal is strong enough to justify a second trial. For AZN, this is a manageable pipeline setback; IONS shareholders face a more meaningful valuation reset since ATTR-CM was a key growth driver for that stock.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 9 $178.49entry
- T+1 · 4mo ago −3.85%α −4.29% · $171.61
- T+5 · 4mo ago −5.15%α −5.02% · $169.29
- T+20 · 3mo ago −9.81%α −12.05% · $160.99
- T+60 · 6w ago −12.10%α −13.73% · $156.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced that the CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary composite endpoint of CV mortality and recurrent CV events versus placebo. The drug was generally well tolerated, but adding it to standard of care including a majority on a stabiliser showed no statistically significant benefit. A prespecified monotherapy subgroup showed nominally significant fewer events, while no effect was seen in patients on stabiliser at baseline. The failure is a setback for AZN's pipeline in a large indication, but the stock impact may be moderated by the company's diversified portfolio and the monotherapy signal.
Key Facts
- CARDIO-TTRansform Phase III trial did not meet the primary efficacy endpoint of composite CV mortality and recurrent CV events up to 140 weeks.
- Trial enrolled 1,432 participants across 130 sites in 20 countries, randomised 1:1 to eplontersen 45 mg or placebo.
- 57% of patients in each arm received a stabiliser at baseline; a further 24% in each arm initiated a stabiliser during the trial.
- Prespecified monotherapy subgroup showed nominally significant fewer primary composite events; no treatment effect observed in patients on stabiliser at baseline.
- Full data analysis will be shared at the European Society of Cardiology Congress in August 2026.
Financial Impact
The failure reduces the probability of approval for the ATTR-CM indication, which could have been a multibillion-dollar opportunity. No specific financial figures from the filing.
Risk Factors
- Negative trial outcome could lead to write-down of asset value and reduced pipeline confidence.
- Nominal significance in monotherapy subgroup may not be sufficient for regulatory approval without additional trials.
- Competitors with approved stabilisers (tafamidis) maintain market dominance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006554 |
| Document: 0001654954-26-006554-index-headers.html | 0001654954-26-006554 |
| Document: 0001654954-26-006554-index.html | 0001654954-26-006554 |
| Document: 0001654954-26-006554.txt | 0001654954-26-006554 |
Track record
77 reports on AZN
18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers